• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ZimVie Inc. (Amendment)

    2/13/24 5:17:36 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email
    SC 13G/A 1 tv02334-zimvieinc.htm SCHEDULE 13G/A zimvieinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Zimvie Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  98888T107

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  98888T107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    24,421

    7.  SOLE DISPOSITIVE POWER

    1,726,293

    8.  SHARED DISPOSITIVE POWER

    35,272

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,761,565

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.64%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Zimvie Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    10225 Westmoor Drive
    Westminster, CO 80021

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    98888T107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ZIMV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    3/18/2022Neutral
    Guggenheim
    More analyst ratings

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on ZimVie with a new price target

      B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

      4/10/25 12:44:28 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie downgraded by Needham

      Needham downgraded ZimVie from Buy to Hold

      3/13/25 7:58:34 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie upgraded by Needham with a new price target

      Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00

      5/16/24 7:42:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    See more
    • ZimVie Announces Upcoming Changes to Company's Board of Directors

      PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

      3/13/25 4:15:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ZimVie Inc.

      SC 13G - ZimVie Inc. (0001876588) (Subject)

      11/14/24 4:11:11 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      11/14/24 10:58:06 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      10/4/24 1:02:25 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    See more

    $ZIMV
    SEC Filings

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results

      FY2024 Third Party Net Sales from Continuing Operations of $449.7 millionFY2024 Net Loss from Continuing Operations of $(33.8) million; Net Loss margin of (7.5%) FY2024 Adjusted EBITDA[1] from Continuing Operations of $60.0 million; Adjusted EBITDA[1] margin of 13.3%FY2024 GAAP diluted EPS from Continuing Operations of $(1.23) and adjusted diluted EPS[1] of $0.62 PALM BEACH GARDENS, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2

      2/26/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by ZimVie Inc.

      10-Q - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:15:20 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:10:42 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by ZimVie Inc.

      DEFA14A - ZimVie Inc. (0001876588) (Filer)

      3/25/25 8:05:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kuntz Richard

      4 - ZimVie Inc. (0001876588) (Issuer)

      5/9/25 5:34:27 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Asar Vinit K

      4 - ZimVie Inc. (0001876588) (Issuer)

      5/9/25 4:58:13 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Matusinec Karen

      4 - ZimVie Inc. (0001876588) (Issuer)

      5/9/25 4:38:01 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Pioneers the Future of Molar Restoration with New Immediate Molar Dental Implant System

      PALM BEACH GARDENS, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its Immediate Molar Implant System in the United States. ZimVie is expanding its already clinically proven TSX® and T3 PRO® Implant systems with an immediate molar solution, simplifying challenging clinical scenarios for providers and shortening treatment times for patients requiring molar implants. Immediately replacing extracted molars with an implant can be difficult due to the complex multi-rooted anatomy and size of the tooth socket. ZimVie's Immediate Molar Implant System includes specially engineered instru

      4/21/25 8:00:00 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care